Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure

Proceedings of the National Academy of Sciences of the United States of America
V B HardingH A Rockman

Abstract

Chronic human heart failure is characterized by abnormalities in beta-adrenergic receptor (betaAR) signaling, including increased levels of betaAR kinase 1 (betaARK1), which seems critical to the pathogenesis of the disease. To determine whether inhibition of betaARK1 is sufficient to rescue a model of severe heart failure, we mated transgenic mice overexpressing a peptide inhibitor of betaARK1 (betaARKct) with transgenic mice overexpressing the sarcoplasmic reticulum Ca(2+)-binding protein, calsequestrin (CSQ). CSQ mice have a severe cardiomyopathy and markedly shortened survival (9 +/- 1 weeks). In contrast, CSQ/betaARKct mice exhibited a significant increase in mean survival age (15 +/- 1 weeks; P < 0.0001) and showed less cardiac dilation, and cardiac function was significantly improved (CSQ vs. CSQ/betaARKct, left ventricular end diastolic dimension 5.60 +/- 0.17 mm vs. 4.19 +/- 0.09 mm, P < 0.005; % fractional shortening, 15 +/- 2 vs. 36 +/- 2, P < 0.005). The enhancement of the survival rate in CSQ/betaARKct mice was substantially potentiated by chronic treatment with the betaAR antagonist metoprolol (CSQ/betaARKct nontreated vs. CSQ/betaARKct metoprolol treated, 15 +/- 1 weeks vs. 25 +/- 2 weeks, P < 0.0001). Thus, over...Continue Reading

References

Sep 18, 1992·Cell·W J Tang, A G Gilman
Jul 22, 1982·The New England Journal of Medicine·M R BristowE B Stinson
Aug 13, 1993·Cell·R J Lefkowitz
Dec 31, 1997·The American Journal of Cardiology·M Packer
Apr 29, 1998·The Journal of Clinical Investigation·L R JonesM Morad
Jun 17, 1998·Proceedings of the National Academy of Sciences of the United States of America·H A RockmanW J Koch
Jun 9, 1999·Proceedings of the National Academy of Sciences of the United States of America·S EngelhardtM J Lohse
Feb 15, 2000·The Journal of Biological Chemistry·S V Naga PrasadH A Rockman
Apr 26, 2000·Proceedings of the National Academy of Sciences of the United States of America·D C WhiteW J Koch
Jan 4, 2001·Current Opinion in Cardiology·A S Betkowski, P J Hauptman
Jan 6, 2001·The Annals of Pharmacotherapy·S M Hart

❮ Previous
Next ❯

Citations

Feb 21, 2009·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Gerald W Dorn
Aug 11, 2010·Naunyn-Schmiedeberg's Archives of Pharmacology·Sophie GüntherJoachim Neumann
Mar 5, 2005·European Journal of Nuclear Medicine and Molecular Imaging·Cecilia MariniGianmario Sambuceti
Jul 14, 2010·Journal of Cardiovascular Translational Research·Henriette Brinks, Walter J Koch
Jan 20, 2004·Pharmacology & Therapeutics·Nina WettschureckStefan Offermanns
Jun 7, 2005·Trends in Pharmacological Sciences·Peter Molenaar, William A Parsonage
Oct 2, 2003·Journal of Molecular and Cellular Cardiology·Jason A Petrofski, Walter J Koch
Oct 5, 2001·Trends in Genetics : TIG·S V Naga PrasadH A Rockman
Jan 31, 2012·Acta Pharmacologica Sinica·Anthony Yiu Ho Woo, Rui-ping Xiao
Sep 5, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mohsin KhanMark A Sussman
Feb 27, 2007·Nature Medicine·Anastasios LymperopoulosWalter J Koch
Apr 9, 2009·Nature Reviews. Cardiology·Gerald W Dorn
Jul 3, 2004·Nature Reviews. Drug Discovery·Xander H T Wehrens, Andrew R Marks
Jan 29, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Anastasios LymperopoulosWalter J Koch
May 12, 2009·Proceedings of the National Academy of Sciences of the United States of America·Kaoru ItoIssei Komuro
Apr 20, 2004·Assay and Drug Development Technologies·Guido Iaccarino, Walter J Koch
Jan 14, 2003·Annual Review of Physiology·N Frey, E N Olson
Jun 21, 2008·Circulation Research·Leif Erik VingeWalter J Koch
Jun 26, 2010·Circulation Research·Liam M CaseyBurns C Blaxall
Jul 23, 2011·Circulation Research·Stephen L Belmonte, Burns C Blaxall
Dec 20, 2011·Circulation Research·Weizhong ZhuRui-Ping Xiao
Apr 18, 2001·The Journal of Clinical Investigation·S B Liggett
Jun 3, 2006·The Journal of Clinical Investigation·Cinzia PerrinoHoward A Rockman
Aug 19, 2007·The Journal of Clinical Investigation·Hiroyuki NakayamaJeffery D Molkentin
Dec 3, 2011·The Journal of Clinical Investigation·Sanjeewa A GoonasekeraJeffery D Molkentin
Oct 12, 2010·The Journal of Endocrinology·Nabanita S DattaAbdul B Abou-Samra
Apr 24, 2004·Proceedings of the National Academy of Sciences of the United States of America·Amy OdleyGerald W Dorn
Apr 8, 2014·Antioxidants & Redox Signaling·Zheng Maggie HuangWalter J Koch
Sep 11, 2001·Journal of Molecular and Cellular Cardiology·Y SatoE G Kranias
Dec 30, 2008·Heart Failure Reviews·Ali El-Armouche, Thomas Eschenhagen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.